How do adult FSGS clinic nurses explain to Spanish-speaking patients why prednisone must continue even after proteinuria normalizes?

The most consequential adherence error in the adult FSGS clinic involving steroid therapy is a patient who achieves complete remission — proteinuria falling below 300 mg per 24 hours — within the first eight to twelve weeks of prednisone and concludes that the disease has been permanently resolved and that stopping prednisone is safe. The conclusion is mechanistically incorrect in a specific way that the clinic nurse can explain. Primary focal segmental glomerulosclerosis is a disease of the podocytes — the terminally differentiated cells that extend foot processes across the outside of the glomerular capillaries and form the slit diaphragm filtration barrier. The leading hypothesis for primary FSGS pathogenesis is that a circulating permeability factor, produced by an abnormal clone of T lymphocytes or by myeloid cells responding to T cell signals, injures podocyte foot processes directly, causing them to efface — retract, fuse, and lose their interdigitated architecture — disrupting the slit diaphragm and allowing massive quantities of albumin to pass through the glomerular filtration barrier into the urine. The characteristic biopsy finding is diffuse foot process effacement on electron microscopy with no immune complex deposits on immunofluorescence — confirming that the injury is cell-mediated and permeability-factor-driven rather than antibody-mediated like membranous nephropathy. Prednisone suppresses the immune cells producing the circulating permeability factor. As the factor production falls on prednisone, the ongoing podocyte injury decreases, the foot processes partially re-extend, the slit diaphragm partially reconstitutes, and proteinuria falls toward normal. Complete remission — proteinuria below 300 mg per 24 hours — means that the drug is successfully suppressing the circulating permeability factor at this moment in time. It does not mean that the immune cell clone driving the permeability factor has been permanently eliminated or re-educated. Those immune cells remain in the patient's lymphoid tissues; their permeability factor output is merely suppressed by the daily prednisone effect. KDIGO 2021 clinical practice guidelines for FSGS define the treatment course for steroid-sensitive FSGS as follows: prednisone at 1 mg per kilogram per day up to a maximum of 80 mg daily, continued until complete remission is achieved (or for up to sixteen weeks), then maintained at the induction dose for at least two to four weeks after remission before beginning a gradual taper; the full taper from induction dose to discontinuation should extend over an additional four to six months. Total treatment duration from initiation to discontinuation is approximately six months, not two months. The most common error is stopping prednisone at the moment of first complete remission, before the maintenance phase has begun. Published cohort data from NEPTUNE and from the original randomized trials of steroids for FSGS consistently show relapse rates of fifty to seventy percent within two years of stopping steroids, with higher relapse rates in patients who stopped prematurely rather than completing the full taper. The Spanish frame: 'La proteína en la orina llegó a cero porque la cortisona está suprimiendo activamente las células del sistema inmune que producen el factor que daña los filtros del riñón. Ese cero significa que el tratamiento funciona ahora mismo — no que esas células se hayan eliminado de manera permanente. Si para la cortisona hoy, esas células van a retomar la producción del factor en semanas a meses, y la proteína va a volver — con frecuencia a niveles similares o más altos que al principio. El tratamiento completo dura seis meses en total, incluyendo la fase de reducción gradual. Parar en el momento en que la proteína llega a cero es como parar un antibiótico el primer día que baja la fiebre — la infección todavía está suprimida pero no eliminada, y el cuerpo todavía necesita el tratamiento para completar la tarea.' (The protein in the urine reached zero because cortisone is actively suppressing the immune cells that produce the factor that damages the kidney filters. That zero means the treatment is working right now — not that those cells have been permanently eliminated. If you stop cortisone today, those cells will resume producing the factor within weeks to months, and the protein will return — often to similar or higher levels than at the beginning. The complete treatment lasts six months in total, including the gradual reduction phase. Stopping at the moment protein reaches zero is like stopping an antibiotic the first day fever breaks — the infection is still suppressed but not eliminated, and the body still needs the treatment to complete the task.)

Why are NSAIDs contraindicated in nephrotic syndrome and persistent proteinuria, and how do FSGS clinic nurses explain the mechanism to Spanish-speaking patients?

The contraindication to non-steroidal anti-inflammatory drugs in nephrotic syndrome or persistent nephrotic-range proteinuria is based on a specific renal hemodynamic mechanism that the clinic nurse can explain to a Spanish-speaking patient who has taken ibuprofen without incident in the past and does not understand why their FSGS diagnosis changes that. In a healthy individual with normal serum albumin and normal plasma oncotic pressure, the distribution of fluid between the intravascular compartment and the interstitial space is maintained by the balance between hydrostatic pressure (pushing fluid out of the capillaries) and oncotic pressure (pulling fluid back in). Albumin is the primary determinant of plasma oncotic pressure. In nephrotic syndrome — whether from FSGS, membranous nephropathy, minimal change disease, or any other glomerular disease producing more than 3.5 g per 24 hours of proteinuria — massive urinary albumin loss reduces serum albumin to hypoalbuminemic levels. As serum albumin falls, plasma oncotic pressure falls, and fluid shifts progressively from the intravascular compartment to the interstitial space, producing edema. This fluid shift reduces the effective circulating volume available to perfuse the organs, including the kidneys — even when total body sodium and water are increased, as in edematous nephrotic states. In states of reduced effective circulating volume, the kidney activates several compensatory mechanisms to maintain renal blood flow and glomerular filtration rate. The renin-angiotensin-aldosterone system is activated: reduced renal perfusion pressure releases renin from the juxtaglomerular apparatus, producing angiotensin II that constricts the efferent arteriole and stimulates aldosterone-mediated sodium and water retention. The sympathetic nervous system increases renal sympathetic nerve activity, producing afferent arteriolar vasoconstriction. Arginine vasopressin is secreted in response to perceived volume depletion, promoting water retention. Each of these compensatory responses tends to reduce renal blood flow, which would worsen glomerular filtration if not opposed. The countervailing mechanism that maintains GFR under these conditions is the local renal production of prostaglandins — specifically prostaglandin E2 and prostacyclin (PGI2) — by cyclooxygenase-1 in the mesangial cells, glomerular endothelial cells, and the smooth muscle of the afferent arteriole. These prostaglandins vasodilate the afferent arteriole, opposing the SNS-mediated and high-dose angiotensin II-mediated afferent vasoconstriction and maintaining renal blood flow and GFR. In a healthy individual with normal albumin and normal effective circulating volume, renal prostaglandins play a minimal role in maintaining GFR under normal conditions, and NSAID-induced cyclooxygenase inhibition has negligible effect on renal function. In a patient with nephrotic syndrome or persistent proteinuria and hypoalbuminemia, renal prostaglandins are critically important for maintaining GFR — they are the primary mechanism preventing the compensatory RAAS and SNS vasoconstriction from producing ischemic AKI. When a patient with nephrotic syndrome takes an NSAID — ibuprofen, naproxen, ketorolac, celecoxib, or any other COX inhibitor — the cyclooxygenase inhibition eliminates renal prostaglandin production. Without prostaglandin E2 afferent dilation, the compensatory RAAS and SNS afferent vasoconstriction goes unopposed, afferent arteriolar tone increases, renal blood flow falls, and GFR falls acutely. In patients who are also taking ACE inhibitors or angiotensin receptor blockers — commonly prescribed in FSGS for their antiproteinuric and renoprotective effects — the AKI risk is compounded. ACE inhibitors block angiotensin II production, reducing efferent arteriolar tone. Under normal circumstances, efferent constriction by angiotensin II helps maintain intraglomerular hydraulic pressure when afferent tone is increased. By eliminating efferent compensation (ACE inhibitor) and simultaneously eliminating afferent prostaglandin dilation (NSAID), the combination causes glomerular filtration pressure to fall from two directions simultaneously, producing more severe AKI than either agent alone. The mechanism applies at any dose of NSAID, including over-the-counter doses of ibuprofen 200 mg, because even low doses of COX inhibitors effectively suppress renal prostaglandin synthesis. The contraindication is permanent as long as hypoalbuminemia or nephrotic-range proteinuria persists. The Spanish frame: 'El riñón con proteinuria y albúmina baja depende de una sustancia llamada prostaglandina E2 que produce localmente para mantener los vasos de entrada al riñón dilatados y la función renal normal. El ibuprofeno, el naproxeno, y todos los antiinflamatorios no esteroideos bloquean la enzima que produce esa prostaglandina — en su riñón eso elimina la única defensa que tenía para mantener la filtración normal cuando su volumen circulante está reducido. El resultado puede ser una lesión renal aguda en días, no en meses, y puede ocurrir incluso con dosis de venta libre. El paracetamol (Tylenol) no bloquea esa enzima en el riñón y es seguro en las dosis indicadas. Si necesita algo más fuerte que paracetamol, llámenos antes de tomar cualquier antiinflamatorio.' (The kidney with proteinuria and low albumin depends on a substance called prostaglandin E2 that it produces locally to keep the entry vessels to the kidney dilated and kidney function normal. Ibuprofen, naproxen, and all non-steroidal anti-inflammatory drugs block the enzyme that produces that prostaglandin — in your kidney that eliminates the only defense it had to maintain normal filtration when your circulating volume is reduced. The result can be acute kidney injury in days, not months, and can occur even with over-the-counter doses. Acetaminophen (Tylenol) does not block that enzyme in the kidney and is safe at indicated doses. If you need something stronger than acetaminophen, call us before taking any anti-inflammatory.)

What is the mechanism of cyclosporine in primary FSGS and why does abrupt withdrawal cause rapid relapse?

Cyclosporine and tacrolimus (the two calcineurin inhibitors available for FSGS treatment) produce their effect in focal segmental glomerulosclerosis through two distinct and additive mechanisms, and understanding both is essential for the clinic nurse counseling a Spanish-speaking patient who has achieved complete remission and wants to stop the medication. The first mechanism is immunosuppressive and is the one most patients encounter in online searches: calcineurin inhibitors bind to their respective intracellular immunophilins — cyclophilin for cyclosporine, FKBP12 for tacrolimus — forming a complex that inhibits calcineurin phosphatase activity in T lymphocytes. Calcineurin in T cells dephosphorylates NFAT (nuclear factor of activated T cells) transcription factors, which then enter the nucleus and drive production of IL-2 and other pro-inflammatory cytokines that sustain T lymphocyte proliferation and activation. By blocking calcineurin in T cells, cyclosporine and tacrolimus reduce IL-2 production, inhibit T cell activation and proliferation, and reduce the T cell-derived circulating permeability factor production that drives primary FSGS podocyte injury. This is why calcineurin inhibitors are effective in primary FSGS and why proteinuria falls as the T cell-derived permeability factor is suppressed. The second mechanism is direct podocyte stabilization and is the one most patients with FSGS do not know: calcineurin is not only expressed in T lymphocytes — it is also expressed in podocytes, the kidney's filter cells. In podocytes, calcineurin plays a critical role in regulating synaptopodin, an actin-associated protein that is specifically and abundantly expressed in podocyte foot processes. Synaptopodin is a major component of the actin cytoskeletal scaffold that maintains the structural integrity of the podocyte foot processes and slit diaphragm. When calcineurin is active in podocytes, it dephosphorylates synaptopodin at specific serine residues. Dephosphorylated synaptopodin is recognized by cathepsin L — a cysteine protease expressed in podocytes whose activity is upregulated by the FSGS circulating permeability factor — and is cleaved and degraded. The loss of synaptopodin destabilizes the podocyte actin cytoskeleton: without synaptopodin's actin-nucleating and cross-linking activity, the foot process actin network depolymerizes through cofilin-mediated severing, the foot processes retract and efface, and the slit diaphragm is disrupted, allowing proteinuria to develop. Calcineurin inhibitors — by inhibiting calcineurin in podocytes — prevent synaptopodin dephosphorylation. Phosphorylated synaptopodin accumulates in the foot processes and is not recognized by cathepsin L for degradation. The abundance of phosphorylated synaptopodin in the foot processes stabilizes the actin cytoskeleton, maintains foot process architecture, preserves slit diaphragm integrity, and reduces proteinuria. This is a direct, cell-intrinsic, structural effect on the podocyte that operates independently of and additively with the T cell immunosuppressive mechanism. The clinical implication of this second mechanism is that calcineurin inhibitor withdrawal in FSGS causes rapid proteinuria relapse — much more rapidly than the relapse observed after steroid withdrawal — because calcineurin in podocytes reactivates within hours of CNI removal, synaptopodin dephosphorylation and degradation begins within days, and foot process effacement and proteinuria re-emergence follow within one to four weeks. KDIGO 2021 guidelines for primary FSGS recommend that when complete remission is achieved on calcineurin inhibitors, the CNI should be continued for a minimum of twelve months (some protocols specify twenty-four months) before attempting a very slow taper (reducing the dose by no more than twenty-five percent every two to three months). Abrupt cessation after achieving complete remission carries a relapse rate of forty to sixty percent within six months. Concerns about calcineurin inhibitor nephrotoxicity (afferent arteriolar vasoconstriction from CNI effects on vascular smooth muscle, and striped interstitial fibrosis from tubulointerstitial CNI accumulation) are legitimate and are managed through therapeutic drug monitoring: maintaining cyclosporine troughs within the target range of 100 to 175 ng per mL for FSGS protocols substantially reduces nephrotoxicity risk while preserving efficacy. The appropriate response to nephrotoxicity concern is dose reduction to the minimum effective monitored dose, not abrupt cessation after achieving complete remission. The Spanish frame: 'La ciclosporina protege los podocitos — las células filtro de su riñón — de dos maneras al mismo tiempo. La primera es la que encontró en internet: suprime las células T que producen el factor que daña esas células filtro. La segunda es directamente dentro de los podocitos: la ciclosporina bloquea una enzima llamada calcineurina que está dentro de los podocitos y que normalmente degrada una proteína estructural llamada sinaptopodina — el andamio que mantiene la arquitectura de los prolongamientos de los podocitos que forman el filtro. Mientras la ciclosporina bloquea esa calcineurina, la sinaptopodina permanece intacta y el filtro se mantiene. Cuando para la ciclosporina abruptamente, la calcineurina de los podocitos se reactiva en horas, empieza a degradar la sinaptopodina en días, y el filtro comienza a colapsar en una a cuatro semanas. Por eso la proteína volvió tan rápido — más rápido que cuando uno para la cortisona — porque es un efecto estructural directo en las células del riñón, no solo un efecto sobre el sistema inmune.' (Cyclosporine protects the podocytes — your kidney's filter cells — in two ways simultaneously. The first is the one you found online: it suppresses the T cells that produce the factor that damages those filter cells. The second is directly inside the podocytes: cyclosporine blocks an enzyme called calcineurin that is inside the podocytes and that normally degrades a structural protein called synaptopodin — the scaffold that maintains the architecture of the podocyte extensions that form the filter. As long as cyclosporine blocks that calcineurin, synaptopodin remains intact and the filter holds. When you stop cyclosporine abruptly, the calcineurin in the podocytes reactivates within hours, begins degrading synaptopodin within days, and the filter begins to collapse within one to four weeks. That is why the protein returned so quickly — faster than when one stops cortisone — because it is a direct structural effect on the kidney cells, not just an effect on the immune system.)

What distinguishes primary FSGS from secondary FSGS and why does the distinction matter for treatment decisions in the Spanish-speaking patient population?

Focal segmental glomerulosclerosis is a histological pattern on kidney biopsy, not a single disease — the finding of focal (affecting some but not all glomeruli) and segmental (affecting a portion, not the entire circumference, of the affected glomerulus) scarring on light microscopy is the unifying feature, but the underlying causes and the appropriate treatments differ substantially. Understanding this distinction is important for the clinic nurse because secondary FSGS is not treated with the immunosuppressive regimens used for primary FSGS, and treating secondary FSGS with prednisone or calcineurin inhibitors provides no benefit and exposes the patient to substantial side effects. Primary FSGS — the entity discussed throughout this post — is caused by a circulating permeability factor produced by the immune system (presumptively by abnormal T lymphocytes or T lymphocyte-stimulated myeloid cells), evidenced by diffuse foot process effacement on electron microscopy (the ultrastructural hallmark of permeability factor-mediated podocyte injury), absent or non-specific immune complex deposits on immunofluorescence, and clinical features of nephrotic syndrome (typically massive proteinuria greater than 3.5 g per 24 hours, hypoalbuminemia, edema, and hyperlipidemia). Primary FSGS responds to immunosuppressive therapy because the treatment targets the immune cells producing the causative factor. Secondary FSGS represents a heterogeneous group of conditions in which FSGS develops as a consequence of a known non-immune insult to the podocytes or a structural-adaptive mechanism rather than from a circulating permeability factor. The major subtypes include: obesity-related FSGS (glomerular hyperfiltration from increased single-nephron GFR driven by obesity-associated hemodynamic changes — the most common secondary cause in the US Hispanic patient population, in whom obesity prevalence is high; characterized by less severe foot process effacement on EM, slower proteinuria onset, and absence of the acute nephrotic presentation); medication-induced FSGS (heroin nephropathy, pamidronate and zoledronate, interferon alfa and beta, anti-VEGF therapies like bevacizumab); adaptive FSGS in reduced nephron mass (after unilateral nephrectomy, reflux nephropathy with renal scarring, or any cause of nephron loss including prior AKI); APOL1 high-risk variant FSGS in individuals of sub-Saharan African ancestry (APOL1 G1/G2 risk allele homozygosity or compound heterozygosity dramatically increases FSGS risk and produces a more aggressive clinical course, especially the collapsing variant; relevant to African-American and some Afro-Latino patients in the US); HIV-associated nephropathy (HIVAN — produces collapsing FSGS through direct HIV infection of podocytes and mesangial cells and HIV protein-driven transcriptional reprogramming; highly relevant to ensure testing before initiating immunosuppression since HIV-positive FSGS is treated with antiretroviral therapy not prednisone); and genetic FSGS (mutations in NPHS1 (nephrin), NPHS2 (podocin), WT1, TRPC6, INF2, and other podocyte-specific genes — more common in the pediatric population but relevant in adults with family history, consanguinity, or early-onset disease). The FSGS variant on light microscopy provides some additional information: the tip lesion (segmental lesion at the tubular pole) is almost exclusively primary and steroid-responsive; the collapsing variant (podocyte hypertrophy and hyperplasia with global collapse of the tuft) is associated with HIVAN, APOL1 variants, and rarely primary FSGS but has a poor prognosis regardless of cause; the cellular variant may respond to immunosuppression in primary FSGS; the perihilar variant is common in obesity-related and adaptive FSGS and generally does not respond to immunosuppression; the NOS (not otherwise specified) variant is the most common and may be primary or secondary. The clinical distinction of primary from secondary FSGS is based on the biopsy findings (degree of foot process effacement on EM, IF pattern), clinical presentation (acuity, severity of proteinuria, albumin level), exclusion of secondary causes (HIV, hepatitis B, hepatitis C, obesity, medications, family history, APOL1 status if applicable), and occasionally genetic testing when hereditary FSGS is suspected. The significance for the Spanish-speaking FSGS patient is that obesity-related FSGS — the most common secondary cause in this population — is treated with weight loss, RAAS blockade (ACE inhibitor or ARB), and sodium-glucose cotransporter-2 inhibitors (SGLT2i) to reduce glomerular hyperfiltration, not with prednisone. A patient with obesity-related FSGS started on prednisone (because the workup was incomplete and primary vs. secondary distinction was not established) will experience the metabolic complications of corticosteroids including weight gain, glucose intolerance, and hypertension without any therapeutic benefit to the glomerular disease. The clinic nurse serves an important gatekeeping function in ensuring the workup is complete and the distinction is established before initiating immunosuppression. The Spanish frame for discussing this distinction: 'Hay dos tipos principales de FSGS — la primaria, causada por una sustancia que produce el sistema inmune que daña los podocitos, y la secundaria, que es el daño que ocurre como consecuencia de otro problema como la obesidad o ciertos medicamentos o infecciones como el VIH. El tratamiento es completamente diferente: la primaria puede responder a la cortisona y a la ciclosporina porque estas suprime las células inmunes que están causando el daño; la secundaria no responde a la cortisona y tomarla sin necesidad expone a los efectos secundarios sin ningún beneficio. Por eso es importante que el médico haya descartado las causas secundarias antes de iniciar la cortisona.' (There are two main types of FSGS — primary, caused by a substance the immune system produces that damages the podocytes, and secondary, which is damage that occurs as a consequence of another problem such as obesity, certain medications, or infections like HIV. The treatment is completely different: primary may respond to cortisone and cyclosporine because these suppress the immune cells that are causing the damage; secondary does not respond to cortisone and taking it unnecessarily exposes to side effects without any benefit. That is why it is important that the physician has ruled out secondary causes before starting cortisone.)

What are the key Spanish phrases adult FSGS clinic nurses use for proteinuria monitoring conversations, NSAID and medication safety, and explaining the difference between remission and cure?

For explaining why monitoring continues even when the patient feels completely well and proteinuria is in remission: 'La FSGS puede estar recayendo en los riñones antes de que usted note ningún síntoma. Por eso medimos la proteína en la orina en cada visita — incluso cuando se siente bien — porque la proteína sube semanas o meses antes de que regrese la hinchazón o de que la creatinina suba. Si detectamos la proteína subiendo temprano, podemos intervenir antes de que los filtros del riñón sufran daño permanente. Después de completar el tratamiento, las visitas de seguimiento son cada tres a cuatro meses durante los primeros dos años — que es cuando el riesgo de recaída es mayor — y luego cada seis meses después de eso. En casa: si nota espuma en la orina — una espuma que no desaparece en treinta segundos — o si nota que sus tobillos o pies se hinchan de nuevo aunque se sienta bien por lo demás, llámenos el mismo día. Eso puede indicar que la proteína está volviendo antes de la próxima visita programada.' (FSGS can be relapsing in the kidneys before you notice any symptoms. That is why we measure protein in the urine at every visit — even when you feel well — because protein rises weeks or months before swelling returns or creatinine rises. If we detect protein rising early, we can intervene before the kidney filters suffer permanent damage. After completing treatment, follow-up visits are every three to four months during the first two years — when relapse risk is highest — and then every six months after that. At home: if you notice foam in the urine — a foam that does not disappear in thirty seconds — or if you notice your ankles or feet swelling again even though you feel well otherwise, call us the same day. That may indicate protein is returning before the next scheduled visit.) For the NSAID safety conversation — to be given to every FSGS patient and their household: 'Los medicamentos antiinflamatorios no esteroideos — ibuprofeno (Advil, Motrin), naproxeno (Aleve), diclofenaco, ketorolaco, y todos los demás antiinflamatorios de venta libre o con receta — están completamente contraindicados para usted mientras tenga la FSGS y mientras su nivel de albúmina en la sangre no sea completamente normal. Pueden causar insuficiencia renal aguda en días cuando usted tiene proteína en la orina o la albúmina está baja, porque el riñón en esas condiciones depende de una sustancia llamada prostaglandina para mantener su función. Los antiinflamatorios bloquean esa prostaglandina. Para el dolor de cabeza, el dolor muscular leve, y la fiebre: el paracetamol (Tylenol) hasta cuatro gramos al día en adultos es seguro. Para cualquier dolor que necesite más que paracetamol — dolor de espalda, dolor de articulaciones, dolor de muelas — llámenos antes de tomar cualquier cosa. Si un médico de urgencias, un dentista, o cualquier otro médico le receta un antiinflamatorio, dígales: tengo FSGS y los antiinflamatorios están contraindicados para mi riñón. Le pedimos también que lleve esta tarjeta de nefrología en su billetera para que cualquier médico pueda verla en una emergencia.' (Non-steroidal anti-inflammatory medications — ibuprofen (Advil, Motrin), naproxen (Aleve), diclofenac, ketorolac, and all other over-the-counter or prescription anti-inflammatory drugs — are completely contraindicated for you as long as you have FSGS and as long as your albumin level in the blood is not completely normal. They can cause acute kidney failure in days when you have protein in the urine or albumin is low, because the kidney under those conditions depends on a substance called prostaglandin to maintain its function. Anti-inflammatory drugs block that prostaglandin. For headache, mild muscle pain, and fever: acetaminophen (Tylenol) up to four grams per day in adults is safe. For any pain that needs more than acetaminophen — back pain, joint pain, toothache — call us before taking anything. If an emergency physician, dentist, or any other doctor prescribes an anti-inflammatory, tell them: I have FSGS and anti-inflammatory drugs are contraindicated for my kidney. We also ask you to carry this nephrology card in your wallet so any physician can see it in an emergency.) For explaining remission versus cure: 'La remisión significa que el tratamiento está controlando la enfermedad lo suficientemente bien como para que la proteína en la orina esté cerca de cero ahora mismo. No significa que la enfermedad se curó de manera permanente. En la FSGS, las células del sistema inmune que producen el factor que daña los filtros del riñón siguen presentes en su cuerpo durante la remisión — están suprimidas por el tratamiento. Y en el caso de la ciclosporina, el riñón mismo depende de la ciclosporina para mantener la estructura de los filtros desde adentro. Por eso el tratamiento debe continuar aunque los análisis estén perfectos. Si en algún momento tiene dudas sobre si seguir alguno de sus medicamentos renales, llámenos antes de hacer cualquier cambio — el mayor riesgo no es seguir el tratamiento el tiempo necesario, sino la recaída que puede dañar permanentemente los filtros del riñón que tiene.' (Remission means that the treatment is controlling the disease well enough that protein in the urine is close to zero right now. It does not mean the disease was permanently cured. In FSGS, the immune cells that produce the factor that damages the kidney filters are still present in your body during remission — they are suppressed by the treatment. And in the case of cyclosporine, the kidney itself depends on the cyclosporine to maintain the structure of the filters from the inside. That is why treatment must continue even when all tests are perfect. If at any point you have doubts about continuing any of your kidney medications, call us before making any changes — the greatest risk is not continuing the treatment for the necessary time, but the relapse that can permanently damage the kidney filters you have.)

Spanish for adult FSGS clinic nurses — the patient who stopped prednisone when proteinuria normalized not knowing that steroid-responsive focal segmental glomerulosclerosis requires the complete induction course before tapering begins and that premature cessation is the primary driver of the fifty to seventy percent relapse rate; the patient with persistent nephrotic proteinuria who took ibuprofen for back pain not knowing that hypoalbuminemia makes the kidney dependent on prostaglandin E2-mediated afferent arteriolar dilation to maintain GFR and that NSAID cyclooxygenase inhibition removes that protection; and the patient with steroid-resistant FSGS in complete remission on cyclosporine who stopped it abruptly not knowing that calcineurin inhibitor withdrawal dephosphorylates synaptopodin in podocyte foot processes destabilizing the actin cytoskeleton and driving relapse in forty to sixty percent of patients within weeks

The adult FSGS clinic nurse’s communication challenge

Focal segmental glomerulosclerosis (FSGS) is the leading cause of nephrotic syndrome in adults in the United States, and one of the most common causes of end-stage renal disease in young and middle-aged adults in the populations served by US nephrology clinics — including the predominantly Hispanic patient populations of California, Texas, Arizona, and Illinois where ClinicaLingo’s scenarios are anchored. Primary FSGS — the immune-mediated form caused by a circulating T lymphocyte-derived permeability factor that directly injures the podocyte foot processes forming the glomerular filtration slit diaphragm — is a disease where treatment response is real and observable (proteinuria normalization, albumin recovery, edema resolution) but where the underlying podocyte vulnerability persists through and after remission, producing a high relapse rate when treatment is stopped prematurely or incorrectly. The visible indicators of treatment success in FSGS carry precise mechanistic meanings that differ from what patients naturally infer from them, and those inferential gaps drive the most common and most consequential adherence errors the FSGS clinic nurse encounters.

Three structural misunderstandings cluster in the FSGS clinic. The first is the equation of proteinuria normalization with disease resolution: a patient who achieves complete remission on prednisone — proteinuria falling below 300 mg per 24 hours, albumin normalizing, edema resolving — concludes that the kidney has been healed and that the prednisone course can be stopped, not understanding that prednisone suppresses the circulating permeability factor every day it is taken and that stopping it before the six-month induction-plus-taper course is complete allows the factor to re-emerge and re-injure the podocytes. The second is the failure to identify NSAIDs as specifically and acutely dangerous in nephrotic syndrome: a patient who has taken ibuprofen without incident for years takes it for an acute pain problem, not knowing that nephrotic-range hypoalbuminemia changes the kidney’s fundamental dependence on renal prostaglandins to maintain GFR and that NSAID-induced cyclooxygenase inhibition can cause severe acute kidney injury within days in a patient who was previously tolerating their kidney disease without problems. The third is the misunderstanding of calcineurin inhibitor withdrawal in steroid-resistant FSGS: a patient in complete remission on cyclosporine stops it abruptly based on a reasonable concern about long-term immunosuppressant effects, not knowing that cyclosporine protects the kidney through a direct structural mechanism in the podocyte (maintaining synaptopodin in its phosphorylated, actin-stabilizing form) that is lost within hours of the drug being removed, driving relapse rates of forty to sixty percent within weeks.

Three conversations from the adult FSGS clinic:

Scenario 1: Luis Felipe Morales-García — 36 years old, Chicago, Illinois

Luis Felipe Morales-García was a warehouse supervisor at a freight distribution center in Chicago who had noticed over three weeks that his ankles swelled progressively throughout his shifts and that his eyes were puffy each morning on waking. He had attributed the leg swelling to the long hours of standing and the morning eye puffiness to fatigue. His wife noticed that his urine had been persistently foamy — a thick, persistent foam that did not dissipate when the toilet was flushed, distinct from the transient surface foam that appears briefly after urination in normal physiology. She insisted he see their primary care physician, who found 4+ protein on urine dipstick and immediately referred him to nephrology.

His nephrology workup confirmed the clinical picture of nephrotic syndrome: 24-hour urine protein 9.4 g per day; serum albumin 1.8 g/dL (normal range 3.5–5.0 g/dL); total cholesterol 398 mg/dL; triglycerides 542 mg/dL; creatinine 0.9 mg/dL (eGFR greater than 90 mL/min/1.73 m² — GFR preserved at presentation despite massive proteinuria). Serology for secondary causes of FSGS returned negative: HIV antigen/antibody combination assay negative; hepatitis B surface antigen negative; anti-HCV antibody negative; antinuclear antibody and anti-double-stranded DNA antibody negative; serum protein electrophoresis showed no monoclonal protein. His BMI was 26 (normal, excluding obesity-related FSGS as primary etiology). His medication list included no nephrotoxic agents (no NSAIDs, no bisphosphonates, no interferon, no heroin). Echocardiogram showed no signs of amyloid cardiomyopathy. Kidney biopsy was performed.

Light microscopy showed focal and segmental sclerosis in the perihilar region of twelve of twenty-two glomeruli sampled, with accumulation of hyaline material and foam cells at the affected segments; several glomeruli showed early segmental collapse. Electron microscopy demonstrated diffuse podocyte foot process effacement affecting greater than 85 percent of glomerular capillary loops examined — the ultrastructural finding that distinguishes primary immune-mediated FSGS (diffuse, severe effacement reflecting circulating permeability factor-driven podocyte injury) from secondary adaptive FSGS (partial, less severe effacement). Immunofluorescence showed no significant deposits of IgG, IgA, IgM, C3, C4d, or C1q — the absence of immune complex deposits confirming that the injury was not antibody-mediated. The diagnosis was primary FSGS, NOS (not otherwise specified) variant.

Treatment was initiated with prednisone 1 mg/kg/day (80 mg daily for his weight of 81 kg), per KDIGO 2021 guidelines for initial treatment of primary FSGS. Concurrent treatments included lisinopril 20 mg daily for antiproteinuric and renoprotective effect, furosemide 40 mg daily for edema management, atorvastatin 40 mg daily for the nephrotic hyperlipidemia, and dietary sodium restriction below 2 grams per day. Luis was counseled on the treatment plan at the initial visit by clinic nurse Catalina Reyes-Morales, who explained that the prednisone course would be long — a full six months from initiation to completion including the taper — and that they would monitor urine protein and kidney function closely at monthly visits.

The induction phase proceeded with the steroid responsiveness the biopsy characteristics had suggested. At week four, proteinuria had fallen from 9.4 to 3.6 g per 24 hours — significant improvement, albumin had risen to 2.4 g/dL, but still in the nephrotic range and the edema was only partially resolved. At week eight, the clinic called Luis to report his results: 24-hour urine protein 0.24 g per day — below the 0.3 g threshold defining complete remission. Albumin was 3.6 g/dL — normal range. Creatinine stable at 0.9 mg/dL. Cholesterol had normalized to 196 mg/dL. His edema had completely resolved. He had returned to his regular work schedule without difficulty. By every observable measure, the nephrotic syndrome had resolved.

Luis came to his month-two visit with a question that had been developing since the week-eight results. He was feeling completely well. His face looked normal again. His weight had increased 8 pounds — he had noticed the truncal weight gain and the facial fullness that were recognizable as steroid side effects. He had researched prednisone and knew about the long-term risks: glucose intolerance, bone loss, cataracts, mood effects, adrenal suppression. He told nurse Reyes-Morales that since all his tests were normal — protein essentially zero, albumin normal, cholesterol normal — he wanted to discuss whether continuing the high-dose prednisone was still necessary, and specifically whether the results meant the kidney had recovered and the medication could be stopped.

Nurse Reyes-Morales had had this conversation many times in the FSGS clinic. The clinical picture was precisely the one that triggered the most common and most consequential adherence error in steroid-sensitive FSGS: a patient whose visible indicators were excellent inferring that the underlying disease process was resolved when what they were seeing was the ongoing result of the drug suppressing the process. She asked whether she could walk him through what the normal protein result actually meant about the state of his kidney disease, because the mechanism would explain why stopping the prednisone now — when every result was normal — was the highest-risk moment in his treatment.

She began with the biopsy. His kidney biopsy had confirmed what the clinical picture suggested: his FSGS was a disease of the podocytes — the specialized cells whose long cytoplasmic extensions, called foot processes, interdigitate across the outside of every glomerular capillary and form the filtration barrier that keeps proteins like albumin in the blood. The electron microscopy had shown that more than 85 percent of his glomerular capillary loops had complete foot process effacement — the foot processes had retracted and fused, disrupting the slit diaphragms between them and allowing albumin to pour through into the urine. In primary FSGS, the mechanism driving that foot process effacement was a circulating permeability factor — a molecule produced by abnormal T lymphocytes in his immune system that directly injured the podocyte cytoskeleton, causing the foot processes to retract. The immunofluorescence finding of no immune complex deposits had confirmed that the injury was from that factor, not from antibodies depositing in the kidney.

Prednisone, she continued, suppressed the T lymphocytes that were producing that permeability factor. Every day he took prednisone, it reduced the activity of those immune cells and reduced the amount of permeability factor circulating in his blood. As the permeability factor production fell, the foot processes began to re-extend, the slit diaphragms partially reconstituted, and the albumin leakage fell toward normal. The 0.24 g per day result they were seeing at week eight meant that the prednisone was successfully suppressing those T lymphocytes right now, today. What it did not mean was that those T lymphocytes had been permanently eliminated from his immune system or that they had been permanently re-educated not to produce the permeability factor. Those cells were still there, in his lymphoid tissues throughout his body, their permeability factor production merely held in check by the daily prednisone effect.

“Si para la cortisona hoy,” Nurse Reyes-Morales said, “esas células T van a regresar gradualmente a producir el factor de permeabilidad en las semanas o meses después de que la cortisona se va del cuerpo. Los podocitos, que todavía están en el proceso de recuperar su estructura, van a volver a dañarse. Y los datos publicados de pacientes con FSGS que alcanzaron la remisión completa con esteroides nos dicen que el cincuenta al setenta por ciento recae dentro de los dos años siguientes de parar los esteroides — y ese porcentaje es mayor cuando el tratamiento se para demasiado temprano antes de completar la reducción gradual.”

(If you stop the cortisone today, those T cells are going to gradually return to producing the permeability factor in the weeks or months after the cortisone leaves the body. The podocytes, which are still in the process of recovering their structure, are going to be damaged again. And the published data from patients with FSGS who achieved complete remission with steroids tell us that fifty to seventy percent relapse within the two years following stopping steroids — and that percentage is higher when treatment is stopped too early before completing the gradual reduction.)

Luis asked the practical question that followed from this: how long did the treatment actually need to continue? Reyes-Morales explained the KDIGO guideline: the prednisone would be maintained at the full induction dose of 80 mg daily for at least two more weeks — to let the foot processes consolidate their recovery — before beginning a slow, stepwise taper. The taper would reduce the dose by approximately 10 mg every two weeks, reaching 30 mg by week sixteen, then 5 mg every two weeks from there to zero over another ten weeks. By the six-month mark from the start of treatment, they expected to have completed the full taper. Total treatment was six months, not two months.

She also addressed the side effects directly. The weight gain and facial changes he had noticed were real — truncal fat redistribution and facial fullness from glucocorticoid effect on fat distribution were common at his dose. She explained that as the dose tapered starting in two weeks, those effects would begin to recede. By month four, he would be on a much lower dose; by month six, off prednisone entirely. The bone protection conversation was also held: he was started on calcium 1,200 mg plus vitamin D 800 IU daily, and a baseline DEXA scan was ordered. His glucose was 98 mg/dL at this visit — within normal range, consistent with his BMI, and would be monitored monthly during the high-dose period.

Luis agreed to continue the full course. Over the subsequent months, the taper proceeded as planned: 80 mg to 40 mg over eight weeks, then 40 to 10 mg over eight more weeks, then 10 to 0 mg over the final six weeks. At the six-month mark: proteinuria 0.18 g per 24 hours (complete remission maintained through the taper); albumin 4.0 g/dL; creatinine 0.9 mg/dL; cholesterol 188 mg/dL. His steroid side effects resolved within four weeks of completing the taper — the facial fullness resolved, weight returned to baseline, and glucose monitoring confirmed no lasting glycemic effect.

At twelve months off prednisone, proteinuria had risen to 0.82 g per 24 hours — a partial relapse, below the 3.5 g nephrotic threshold but above complete remission, with albumin 3.1 g/dL. His rheumatologist and nephrologist elected to treat this partial relapse with a shorter course of prednisone 60 mg daily tapering over three months rather than the full six-month induction. Proteinuria returned to 0.21 g per 24 hours at the end of the course. This relapse pattern — achieving complete remission with the full course, then experiencing a partial relapse at twelve months requiring re-treatment — was the natural history of steroid-sensitive, frequently relapsing FSGS, the more favorable of the two long-term trajectories (the other being steroid resistance requiring calcineurin inhibitors). The fact that Luis had completed the full induction-plus-taper course on the first attempt, rather than stopping at week eight, was the reason his first relapse was partial (0.82 g) rather than full-blown nephrotic (likely 8–10 g) — and the reason the re-treatment was shorter and simpler.

Scenario 2: Sandra Espinoza-Cisneros — 24 years old, San Antonio, Texas

Sandra Espinoza-Cisneros was a nursing student in her third year at a health sciences university in San Antonio who had been found to have 3+ proteinuria on a routine pre-employment screening urinalysis required for her upcoming clinical placement at a major hospital system. She had no history of kidney disease, no edema, and no prior abnormal urinalysis. The result was unexpected. Her primary care physician confirmed the proteinuria on a repeat dipstick and referred her to nephrology.

Nephrology workup revealed: 24-hour urine protein 5.8 g per day; serum albumin 2.6 g/dL (reduced from normal 3.5–5.0 g/dL, indicating early hypoalbuminemia from ongoing protein losses); creatinine 0.8 mg/dL (eGFR greater than 90 mL/min/1.73 m²); cholesterol 286 mg/dL; triglycerides 342 mg/dL; blood pressure 122/78 mmHg. Secondary causes excluded: HIV antigen/antibody negative; hepatitis B and C negative; ANA negative; parvovirus B19 IgM antibody negative; SPEP without paraprotein; no nephrotoxic medications; BMI 22 (not obesity-related). Bilateral lower extremity edema was minimal at presentation (trace bilateral ankle pitting). Kidney biopsy confirmed primary FSGS, tip lesion variant: the segmental sclerosis was localized to the glomerular tip — the segment adjacent to the origin of the proximal tubule — with endocapillary hypercellularity at the tip; electron microscopy showed diffuse foot process effacement greater than 80 percent; immunofluorescence showed no significant immune complex deposits. Tip lesion FSGS is associated with steroid responsiveness rates approaching 50–70 percent, higher than the NOS variant, and is considered a favorable prognostic indicator in primary FSGS.

Treatment was initiated: prednisone 1 mg/kg/day (60 mg daily for her 61 kg weight); lisinopril 10 mg daily for antiproteinuric effect; furosemide 20 mg PRN for edema; atorvastatin 20 mg. She was a nursing student and understood the basic framework of her treatment; she was engaged and adherent, attending all follow-up visits.

She demonstrated partial steroid responsiveness. At week eight, proteinuria had fallen to 3.1 g per 24 hours; at week twelve, to 2.3 g per 24 hours; at week sixteen (the end of the full-dose induction period), 1.9 g per 24 hours — a meaningful reduction but not complete remission (below 0.3 g). She was declared steroid-resistant for complete remission though steroid-sensitive for partial remission. After completing the prednisone taper over six months, she was started on mycophenolate mofetil 1,500 mg twice daily (an alternative immunosuppressive for steroid-resistant or partially-responsive primary FSGS, used to further reduce proteinuria toward complete remission) plus continued lisinopril 10 mg daily.

Over the subsequent nine months on mycophenolate, proteinuria gradually improved: from 1.9 g per 24 hours at the end of prednisone to 1.4, then 1.1, then at the most recent visit 1.1 g per 24 hours — stable partial remission. Albumin was 3.2 g/dL — below normal but measurably improved from the 2.6 g/dL at presentation, reflecting the partial reduction in urinary albumin losses. Creatinine remained stable at 0.8 mg/dL. Her edema was mild at baseline visits — trace bilateral ankle swelling at the end of a long day on clinical placement, resolving overnight. She had completed her clinical placements and was working part-time as a patient care technician while finishing her degree.

Eleven months after her FSGS diagnosis, Sandra developed an acute-onset right-sided lower back pain radiating down the right leg to the foot — the pattern of L4–L5 disc herniation with right S1 radiculopathy. She went to an urgent care clinic affiliated with a different health system from her nephrology clinic. The urgent care physician, reviewing her medication list, saw lisinopril and mycophenolate but did not recognize the clinical significance of the combination in the context of active proteinuria and partial nephrotic syndrome. He prescribed ibuprofen 600 mg three times daily with a take-as-needed instruction for up to seven days, for acute musculoskeletal and neuropathic pain.

Sandra began ibuprofen. She had taken 200–400 mg of ibuprofen many times before her FSGS diagnosis for menstrual cramps and minor injuries without any kidney symptoms and without any medical provider ever suggesting it was contraindicated. She reasoned that the FSGS was in partial remission and that the proteinuria was “low” — 1.1 g per day, which she understood from her nursing coursework to be subnephrotic — and that the ibuprofen was from a physician who had reviewed her medications.

On day five of ibuprofen 600 mg three times daily, Sandra noticed that she had urinated less than her usual volume over the prior twenty-four hours and that both ankles were more swollen than her baseline trace edema — progressing to 1+ pitting bilaterally. On day seven, she checked her blood pressure at a pharmacy kiosk: 144/92 mmHg (up from her usual 118/74 mmHg). Her primary care physician ordered stat labs: creatinine 2.2 mg/dL — up from baseline 0.8 mg/dL over seven days. Stage 2 AKI (greater than twofold creatinine rise from baseline). She was contacted by the nephrology clinic and instructed to stop ibuprofen immediately and present the following morning.

At the nephrology visit, clinic nurse Elena Vargas-Torres had the conversation that Sandra, as a nursing student, found both clinically urgent and educationally important — because she would counsel patients in exactly this situation for the rest of her career.

Vargas-Torres explained why ibuprofen was specifically dangerous in Sandra’s kidney situation, even at a dose she had previously tolerated for years. She began with the albumin. Sandra’s albumin was 3.2 g/dL. Normal serum albumin was 3.5–5.0 g/dL. That 0.3 g below normal was not simply a low test result — it reflected a real reduction in the plasma oncotic pressure that kept fluid inside the bloodstream rather than leaking into the tissues. Albumin was the primary protein holding fluid in the vascular space; when albumin fell even modestly, the balance between hydrostatic pressure (pushing fluid out of capillaries) and oncotic pressure (pulling fluid back in) shifted toward fluid extravasation into tissues. Her trace bilateral ankle edema was the visible consequence of this reduced oncotic pressure: fluid was continuously leaking out of the intravascular space faster than it could be retained, so her effective circulating blood volume — the volume of blood actually available to perfuse organs — was mildly reduced even when her total body water was normal or increased.

In that state of mildly reduced effective circulating volume, Vargas-Torres continued, Sandra’s kidney was running a compensatory program. The renin-angiotensin-aldosterone system had a slightly elevated baseline activity — the mild volume reduction had triggered a small but persistent increase in angiotensin II and aldosterone, producing mild compensatory fluid retention. The sympathetic nervous system was also slightly upregulated, contributing to the afferent arteriolar vasoconstriction that was partly responsible for her slightly higher-than-usual blood pressure. Both of these compensatory mechanisms tended to reduce renal blood flow, which would reduce GFR if not opposed. The opposing mechanism — the one maintaining her GFR at 0.8 mg/dL creatinine through her partial nephrotic state — was local renal prostaglandin production. The mesangial cells and afferent arteriolar smooth muscle cells in Sandra’s kidneys were continuously producing prostaglandin E2 and prostacyclin through the cyclooxygenase-1 enzyme. These prostaglandins vasodilated the afferent arteriole, opposing the RAAS- and SNS-mediated afferent vasoconstriction and maintaining renal blood flow and GFR. In her situation — partial nephrotic syndrome with mild hypoalbuminemia and mild reduced effective circulating volume — those prostaglandins were the critical mechanism keeping her GFR stable at a creatinine of 0.8 mg/dL.

Ibuprofen, Vargas-Torres explained, inhibited the cyclooxygenase-1 enzyme. In a healthy person with normal albumin and normal plasma volume, inhibiting cyclooxygenase-1 in the kidney had minimal effect on GFR because prostaglandins were not playing a significant role in maintaining GFR under normal volume conditions. In Sandra, with hypoalbuminemia and reduced effective circulating volume, inhibiting cyclooxygenase-1 eliminated the prostaglandin E2 that was vasodilating her afferent arteriole and compensating for the RAAS and SNS vasoconstriction. Without the prostaglandin opposition, the afferent arteriolar tone increased, renal blood flow fell, and GFR fell sharply. The compounding factor was the lisinopril. Lisinopril blocked ACE, preventing angiotensin II formation, reducing efferent arteriolar tone. Normally, efferent constriction by angiotensin II maintained intraglomerular hydraulic pressure when afferent tone was increased. With lisinopril eliminating the efferent compensation and ibuprofen eliminating the afferent prostaglandin dilation, the glomerular filtration pressure was reduced from two directions simultaneously — the combined effect producing the 2.2 mg/dL creatinine rather than either mechanism alone.

“El ibuprofeno hizo esto en siete días,” Vargas-Torres said. “Y usted lo ha tomado antes sin problema — por eso es tan importante entender que la FSGS cambió algo en cómo funciona su riñón. Antes del diagnóstico, su albúmina era normal y su riñón no dependía de las prostaglandinas para mantener su función. Ahora que tiene poca albúmina y proteína en la orina, esa dependencia es parte de cómo su riñón funciona todos los días. El ibuprofeno quitó esa protección.”

(Ibuprofen did this in seven days. And you have taken it before without problem — that is why it is so important to understand that the FSGS changed something in how your kidney functions. Before the diagnosis, your albumin was normal and your kidney did not depend on prostaglandins to maintain its function. Now that you have low albumin and protein in the urine, that dependence is part of how your kidney functions every day. Ibuprofen removed that protection.)

Ibuprofen was discontinued. Intravenous hydration was administered over twenty-four hours. Lisinopril was held for forty-eight hours during the acute phase and restarted at 5 mg once creatinine stabilized. At seventy-two hours, creatinine had improved to 1.2 mg/dL — meaningfully reduced from 2.2 mg/dL but not back to the pre-NSAID baseline of 0.8 mg/dL. At four weeks, creatinine stabilized at 1.1 mg/dL. The difference between 0.8 mg/dL (pre-NSAID) and the new stable 1.1 mg/dL (post-AKI) represented permanent nephron loss from the seven-day AKI episode — approximately a 25 percent reduction in GFR that would not recover, because tubular injury from ischemic AKI produces irreversible nephron dropout at the rate that corresponds to the severity and duration of the ischemic insult.

Sandra received a nephrology wallet card listing every NSAID by both generic and brand name: ibuprofen (Advil, Motrin, Nuprin), naproxen (Aleve, Naprosyn, Anaprox), diclofenac (Voltaren), ketorolac (Toradol), celecoxib (Celebrex), indomethacin, meloxicam, piroxicam — all permanently contraindicated as long as she had FSGS or hypoalbuminemia. She was instructed that acetaminophen (Tylenol) up to 4 grams per day in adults was safe and was the indicated first-line pain agent. For pain beyond acetaminophen, she was instructed to call the nephrology clinic before taking any medication to allow the team to identify safe alternatives (including ice, physical therapy for the disc herniation, gabapentinoids for the neuropathic component, and topical diclofenac gel if essential — noting that topical NSAIDs at therapeutic doses in adults have minimal systemic absorption and negligible renal prostaglandin inhibition, though they would be used with caution). The urgent care clinic was contacted and a note was added to her electronic record visible across health systems.

Scenario 3: Ramón García-Torres — 50 years old, Los Angeles, California

Ramón García-Torres was a restaurant owner in Los Angeles who had noticed progressive bilateral lower extremity edema and significant fatigue over two months. His primary care physician found 4+ protein on urinalysis and sent urgent nephrology referral labs: 24-hour urine protein 7.8 g per day; serum albumin 1.9 g/dL; creatinine 1.2 mg/dL (eGFR 68 mL/min/1.73 m² — mildly reduced, suggesting some pre-existing nephron loss); cholesterol 412 mg/dL; triglycerides 628 mg/dL; blood pressure 148/92 mmHg.

Secondary causes were excluded: HIV antigen/antibody negative; hepatitis B and C negative; ANA negative; SPEP without paraprotein; no nephrotoxic medications; BMI 28 (slightly overweight but not in the obesity-related FSGS range and clinical presentation more consistent with primary disease given the severity and acuity); no family history of kidney disease. Kidney biopsy was performed. Light microscopy showed focal and segmental glomerulosclerosis, NOS variant, with perihilar sclerosis in 15 of 28 glomeruli sampled; 20 percent interstitial fibrosis and tubular atrophy on Masson trichrome, reflecting moderate pre-existing chronic damage. Electron microscopy showed diffuse foot process effacement greater than 90 percent of capillary loops. Immunofluorescence was negative for immune complex deposits. The diagnosis was primary FSGS, NOS variant, with background chronic kidney disease — a more advanced starting point than many patients, requiring urgent treatment to prevent further GFR decline.

Prednisone 1 mg/kg/day was initiated (80 mg for 81 kg), with lisinopril 20 mg, furosemide 40 mg daily, atorvastatin 40 mg, and dietary sodium restriction. The steroid trial proceeded without the rapid response seen in Scenario 1. At week eight, proteinuria had fallen only to 4.2 g per 24 hours — notable partial improvement but well above the complete remission threshold. At week twelve, 3.6 g per 24 hours. At week sixteen — the end of the KDIGO-recommended induction period — proteinuria was 3.1 g per 24 hours. Ramón was declared steroid-resistant for complete remission. The prednisone was tapered over two months and discontinued. He was started on cyclosporine, the preferred calcineurin inhibitor for steroid-resistant primary FSGS.

Cyclosporine was initiated at 3.5 mg/kg/day divided twice daily (approximately 140 mg BID), with target trough monitoring: the therapeutic window for FSGS in most protocols is 100–175 ng/mL (higher troughs associated with efficacy, lower troughs with reduced nephrotoxicity risk). His trough at four weeks was 145 ng/mL — within the target range. He was also maintained on lisinopril 20 mg daily.

The response was encouraging. At month three on cyclosporine, proteinuria had fallen to 1.8 g per 24 hours (partial remission); albumin 3.0 g/dL; creatinine stable at 1.2 mg/dL. At month six, proteinuria 0.4 g per 24 hours (approaching complete remission); albumin 3.6 g/dL; edema essentially resolved. At month seven: proteinuria 0.1 g per 24 hours (complete remission by the less-than-0.3 g per 24 hours criterion); albumin 4.0 g/dL; creatinine 1.1 mg/dL — mildly improved from 1.2, suggesting that the reduction in proteinuria-driven tubular injury had allowed marginal GFR recovery; cholesterol normalized to 204 mg/dL; edema completely resolved; blood pressure 128/78 mmHg on lisinopril alone.

By month eight, Ramón was the picture of a successful FSGS treatment response. At a family Sunday dinner, his brother-in-law — who had received a kidney transplant three years earlier and was maintained on tacrolimus — mentioned to Ramón that his transplant team was “always trying to lower his immunosuppressant” because “cyclosporine and tacrolimus are hard on the kidneys long-term.” After dinner, Ramón searched online and found several reputable sources discussing calcineurin inhibitor nephrotoxicity (CN-nephrotoxicity): afferent arteriolar vasoconstriction, striped interstitial fibrosis, and a dose-dependent risk of chronic kidney injury with prolonged high-dose CNI use. He also found a general statement in a patient advocacy article that “immunosuppressants can increase cancer risk over time.”

Ramón reasoned as follows: his protein was 0.1 g per 24 hours — essentially zero. His albumin was completely normal. He had no edema. His creatinine was at its best since before his FSGS was diagnosed. The cyclosporine had done its job. The disease was resolved. The risks of continuing it — kidney damage from CNI nephrotoxicity, theoretical cancer risk from ongoing immunosuppression — now outweighed the benefits of a medication treating a disease that was no longer present. He stopped cyclosporine without calling the clinic.

Five weeks later, the nephrology clinic called for the routine monthly monitoring appointment. Ramón disclosed that he had stopped cyclosporine five weeks earlier. Clinic nurse Patricia Gutiérrez-Morales heard the disclosure with concern and asked him to come in immediately for same-day labs. The results: creatinine 1.5 mg/dL (up from 1.1 mg/dL pre-withdrawal — an acute-on-chronic rise); proteinuria 4.8 g per 24 hours (returning to near-initial nephrotic range from 0.1 g per 24 hours in five weeks); albumin 2.4 g/dL (fell from 4.0 g/dL over five weeks — reflecting resumed massive urinary albumin losses); bilateral ankle edema 2+ returning; blood pressure 138/86 mmHg; cyclosporine trough: undetectable (expected given the 12-hour cyclosporine half-life and five weeks off the drug).

Nurse Gutiérrez-Morales prepared to have the conversation she had needed to have with Ramón at his first complete remission visit, about the two mechanisms by which cyclosporine was protecting his kidney — because the second mechanism was the one that explained why the proteinuria had returned so rapidly after he stopped.

The first mechanism, she began, was the one he had already researched: cyclosporine suppressed the T lymphocytes that were producing the circulating permeability factor driving his FSGS. By inhibiting calcineurin in T cells, cyclosporine reduced IL-2 and the cytokine signaling that maintained the T lymphocyte clones responsible for permeability factor production. This reduced the circulating permeability factor, reduced podocyte injury, and allowed foot process recovery and proteinuria normalization. This was the immunosuppressive mechanism he was aware of, and it was real.

The second mechanism, she explained, operated directly inside the podocytes themselves — not in the T cells — and this was the mechanism responsible for the rapid relapse. Calcineurin was not only expressed in T lymphocytes; it was also expressed in podocytes. In podocytes, calcineurin regulated a critical structural protein called synaptopodin. Synaptopodin was an actin-associated protein expressed specifically and abundantly in podocyte foot processes — it was one of the primary structural proteins maintaining the actin cytoskeleton that kept the foot processes extended and the slit diaphragm intact. Calcineurin in podocytes dephosphorylated synaptopodin at specific serine residues. Dephosphorylated synaptopodin was recognized by cathepsin L — a cysteine protease expressed in podocytes — as a substrate for cleavage and degradation. When synaptopodin was degraded, the actin cytoskeleton of the foot processes lost its structural support, the foot processes collapsed and effaced, and the slit diaphragm was disrupted, allowing proteinuria to re-emerge.

Cyclosporine, by inhibiting calcineurin in podocytes (through the same cyclophilin-calcineurin binding mechanism it used in T cells), prevented synaptopodin dephosphorylation. Phosphorylated synaptopodin accumulated in the foot processes and was not recognized by cathepsin L for degradation. The abundance of phosphorylated synaptopodin in the foot processes maintained the actin cytoskeleton, preserved foot process architecture, kept the slit diaphragm intact, and protected against proteinuria — independently of any effect on circulating T cells or permeability factor. This was a direct structural mechanism in the podocyte that operated every minute cyclosporine was present and was lost every minute cyclosporine was absent.

When Ramón stopped cyclosporine, she explained, the calcineurin in his podocytes was no longer inhibited. Calcineurin activity was restored within hours. Within days, calcineurin was dephosphorylating synaptopodin faster than the phosphorylation could be maintained. Within one to two weeks, the dephosphorylated synaptopodin had been degraded by cathepsin L, the foot process actin cytoskeleton had lost its stabilization, and foot process effacement had begun. By week five, the proteinuria was already at 4.8 g per 24 hours. The speed of the relapse was not from re-emergence of the circulating T cell permeability factor (which took longer to reconstitute) — it was primarily from the loss of direct podocyte cytoskeletal protection that had been the second mechanism of cyclosporine all along.

“La ciclosporina no solo le protegía el riñón suprimiendo las células T — le estaba protegiendo el filtro desde adentro del propio filtro,” Gutiérrez-Morales summarized. “Cuando la paró, ese andamio estructural que mantenía los filtros en pie dejó de mantenerse en horas — y los filtros empezaron a colapsar antes de que las células T tuvieran tiempo siquiera de recuperarse. Por eso la recaída fue tan rápida. La proteína que tiene ahora a las cinco semanas es lo que las células filtro hacen cuando pierden ese apoyo estructural repentinamente.”

(Cyclosporine was not only protecting your kidney by suppressing the T cells — it was protecting the filter from inside the filter itself. When you stopped it, the structural scaffold that was keeping the filters standing stopped being maintained within hours — and the filters began to collapse before the T cells even had time to recover. That is why the relapse was so rapid. The protein you have now at five weeks is what the filter cells do when they lose that structural support suddenly.)

She then addressed his concern about cyclosporine nephrotoxicity directly. The concern was legitimate — calcineurin inhibitor nephrotoxicity was a real and dose-dependent risk. The mechanism was specific: CNIs produced afferent arteriolar vasoconstriction by inhibiting calcineurin in vascular smooth muscle, reducing endothelial nitric oxide production and increasing endothelin-1, narrowing the arteriolar lumen and reducing blood flow to the tubules; at high concentrations and over years, CNIs could produce striped interstitial fibrosis from tubular ischemia. The risk was dose- and trough-dependent: his trough of 145 ng/mL was within the FSGS therapeutic range of 100–175 ng/mL and below the nephrotoxicity threshold (above 200 ng/mL being the zone where nephrotoxicity risk accelerated). Monthly trough monitoring was precisely how they managed this: if his trough rose above 175, the dose would be reduced; if it fell below 100 while in complete remission, a stable reduction could be discussed. The response to concerns about nephrotoxicity was dose adjustment with monitoring, not abrupt cessation after achieving complete remission.

The KDIGO 2021 guideline for steroid-resistant FSGS in complete remission on calcineurin inhibitors recommended continuing the CNI for a minimum of twelve to twenty-four months after achieving complete remission before beginning a slow taper — reducing by no more than 25 percent every two to three months. This gradual taper allowed the podocyte calcineurin-synaptopodin system to adapt incrementally to each dose reduction rather than experiencing abrupt loss of synaptopodin stabilization. Abrupt cessation after complete remission, as had just occurred, carried a published relapse rate of 40–60 percent within six months. He was in the majority of patients in that statistic.

Cyclosporine was restarted immediately at the same dose. Over the following six weeks, proteinuria improved from 4.8 to 2.1 g per 24 hours as the podocyte cytoskeletal mechanism was re-established. At four months after restart: proteinuria 0.3 g per 24 hours (at the threshold of complete remission). His creatinine stabilized at 1.3 mg/dL — slightly higher than the 1.1 mg/dL he had reached before the abrupt withdrawal, reflecting the permanent nephron loss from the five-week relapse episode during which heavy proteinuria and tubular injury had produced additional tubular dropout beyond the 20 percent interstitial fibrosis already present at biopsy.

The new treatment plan was designed around the mechanism he now understood: continue cyclosporine at the minimally effective trough (targeting 120–145 ng/mL rather than the prior 145 ng/mL) for at least eighteen months of confirmed complete remission from this point, then reduce by 25 percent every three months over twelve to eighteen months. The slow taper would be the intervention that tested whether his podocytes could maintain the actin cytoskeletal architecture independently of calcineurin inhibition — and if any dose reduction caused proteinuria to rise, it would be reversed immediately rather than continued.

Frequently asked questions

How do adult FSGS clinic nurses explain why prednisone must continue even after proteinuria normalizes?

Prednisone suppresses the T lymphocytes producing the circulating permeability factor that drives podocyte foot process effacement and proteinuria in primary FSGS. Proteinuria normalization on prednisone is the drug successfully suppressing the permeability factor right now — not evidence that those T lymphocyte clones have been permanently eliminated. KDIGO 2021 defines the steroid-sensitive FSGS treatment course as prednisone at the induction dose maintained for at least two to four weeks after achieving complete remission, followed by a six-month taper from initiation to zero — not stopping at first remission. Steroid-sensitive FSGS relapse rates after premature cessation are fifty to seventy percent within two years in published NEPTUNE and single-center cohort data. The Spanish frame: “La proteína en la orina en cero significa que la cortisona está suprimiendo el factor que daña los filtros ahora mismo — no que ese factor se eliminó permanentemente. El tratamiento dura seis meses en total para darle tiempo al sistema de completar la supresión. Parar cuando la proteína llega a cero es parar en el momento de mayor éxito del tratamiento, que es también cuando el riesgo de recaída por parar temprano es máximo.” (Protein in the urine at zero means the cortisone is suppressing the factor that damages the filters right now — not that the factor was permanently eliminated. Treatment lasts six months in total to give the system time to complete the suppression. Stopping when protein reaches zero is stopping at the moment of greatest treatment success, which is also when the risk of relapse from stopping early is highest.)

Why are NSAIDs contraindicated in nephrotic syndrome and what does the mechanism mean for practical nursing instruction?

Nephrotic-range hypoalbuminemia reduces plasma oncotic pressure and effective circulating volume, shifting the kidney into a state of dependence on cyclooxygenase-1-derived prostaglandin E2 and prostacyclin to maintain afferent arteriolar dilation and preserve GFR. In healthy individuals with normal albumin, prostaglandins play a minimal role in maintaining GFR and NSAID-induced COX inhibition is clinically inconsequential for renal function. In nephrotic patients, NSAIDs remove the prostaglandin-dependent afferent dilation that is opposing compensatory RAAS- and SNS-mediated afferent vasoconstriction — collapsing GFR acutely within days. The combination of NSAIDs with ACE inhibitors or ARBs (commonly prescribed in FSGS for renoprotection) compounds the AKI risk by simultaneously eliminating both the afferent prostaglandin dilation (NSAID) and the efferent angiotensin II-mediated compensation (ACE inhibitor). The mechanism applies at OTC doses. The practical instruction: “Ibuprofen, naproxen, diclofenac, ketorolac, celecoxib, and all other NSAIDs are permanently contraindicated as long as you have FSGS or low albumin — even at Advil doses. Acetaminophen up to 4 grams per day is safe. If you need something stronger than acetaminophen, call us before taking anything. Tell every prescriber including dentists and urgent care physicians: I have FSGS and NSAIDs are contraindicated for my kidney. Carry this card.” The contraindication is also covered during every medication reconciliation visit and documented prominently in the allergy/contraindication field of the medical record.

What is the mechanism of calcineurin inhibitor withdrawal relapse in FSGS?

Cyclosporine and tacrolimus prevent FSGS relapse through two simultaneous mechanisms: immunosuppressive T cell calcineurin inhibition reducing the circulating permeability factor, and direct podocyte calcineurin inhibition that maintains synaptopodin in its phosphorylated, protected form. Synaptopodin is an actin-associated protein expressed specifically in podocyte foot processes whose phosphorylated form stabilizes the actin cytoskeleton and prevents foot process effacement; dephosphorylated synaptopodin is cleaved by cathepsin L, destabilizing the cytoskeleton. When calcineurin inhibitors are stopped, podocyte calcineurin reactivates within hours, synaptopodin is dephosphorylated within days, and foot process effacement and proteinuria begin within one to four weeks — faster than the relapse following steroid withdrawal, because this is a direct structural mechanism not an immune reconstitution process. KDIGO 2021 recommends continuing calcineurin inhibitors for a minimum of twelve to twenty-four months after achieving complete remission in steroid-resistant FSGS before beginning a slow taper (25 percent reduction every two to three months). Abrupt cessation after complete remission carries a relapse rate of forty to sixty percent within six months. Concerns about calcineurin inhibitor nephrotoxicity are managed by maintaining troughs within the therapeutic range (100–175 ng/mL for cyclosporine in FSGS protocols) with monthly monitoring, not by stopping the drug when proteinuria normalizes.

How do FSGS clinic nurses explain the difference between remission and cure in adult FSGS to Spanish-speaking patients?

The remission-versus-cure distinction in FSGS is mechanistically specific and differs from the corresponding distinction in other glomerular diseases. In membranous nephropathy, remission reflects depletion of the anti-PLA2R B cell clone; in FSGS, remission reflects suppression of the T lymphocyte-derived circulating permeability factor AND (in calcineurin inhibitor-treated patients) active maintenance of podocyte synaptopodin phosphorylation by the drug. Neither the T lymphocyte clone driving the permeability factor nor the dependency of the podocyte cytoskeleton on calcineurin inhibition is eliminated during remission. The Spanish frame: “En la FSGS, la remisión significa que el tratamiento está haciendo dos cosas al mismo tiempo: suprimiendo las células del sistema inmune que producen el factor que daña los filtros, y en el caso de la ciclosporina, manteniendo activamente la estructura de los propios filtros desde adentro. Cuando la proteína en la orina llega a cero, ambas cosas están ocurriendo simultáneamente. Si el tratamiento se para, ambas cosas se pierden — primero la estructura de los filtros (en horas a días para la ciclosporina), luego la supresión del factor dañino (en semanas). La enfermedad sigue estando presente durante la remisión — está controlada por el tratamiento activo, no curada de manera permanente.” (In FSGS, remission means the treatment is doing two things simultaneously: suppressing the immune cells that produce the factor that damages the filters, and in the case of cyclosporine, actively maintaining the structure of the filters themselves from the inside. When protein in the urine reaches zero, both things are occurring simultaneously. If treatment is stopped, both things are lost — first the structure of the filters (within hours to days for cyclosporine), then the suppression of the damaging factor (within weeks). The disease is still present during remission — it is controlled by active treatment, not permanently cured.)

What FSGS monitoring red flags should Spanish-speaking patients be taught to recognize at home?

Three categories of observation require same-day contact with the nephrology clinic. Proteinuria signs: “Si nota espuma persistente en la orina — una espuma densa que no desaparece en treinta segundos cuando el inodoro está lleno de agua — es probable que la proteína en la orina esté subiendo de nuevo. La espuma es una señal más temprana que la hinchazón y puede aparecer semanas antes de que los resultados cambien en las analíticas del laboratorio. No espere a la próxima cita programada.” (If you notice persistent foam in the urine — a thick foam that does not disappear in thirty seconds when the toilet is full of water — it is likely that protein in the urine is rising again. Foam is an earlier sign than swelling and can appear weeks before results change in laboratory tests. Do not wait for the next scheduled appointment.) Edema signs: “Si los tobillos o los pies se hinchan de nuevo y el edema no desaparece completamente después de dormir toda la noche con los pies elevados, o si la hinchazón aparece en las piernas, el abdomen, o alrededor de los ojos, llámenos ese mismo día. El edema que regresa puede indicar que la proteína está subiendo y que la albúmina está cayendo.” (If ankles or feet swell again and the edema does not completely disappear after sleeping all night with feet elevated, or if swelling appears in the legs, abdomen, or around the eyes, call us that same day. Returning edema can indicate that protein is rising and albumin is falling.) Clot warning: “La FSGS con proteína alta en la orina aumenta el riesgo de coágulos en las venas profundas de las piernas o en los pulmones, porque la pérdida de proteínas anticoagulantes en la orina desbalancea el sistema de coagulación. Si nota dolor o hinchazón en una pierna sin causa aparente, o si siente falta de aire repentina o dolor en el pecho al respirar, vaya a urgencias inmediatamente y diga que tiene FSGS con síndrome nefrótico.” (FSGS with high protein in the urine increases the risk of clots in the deep veins of the legs or in the lungs, because the loss of anticoagulant proteins in the urine unbalances the clotting system. If you notice pain or swelling in one leg without apparent cause, or if you suddenly feel short of breath or chest pain when breathing, go to the emergency department immediately and say you have FSGS with nephrotic syndrome.)